Literature DB >> 17243163

A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas.

Tongsheng Wang1, Xinmin Zhang, Laura Obijuru, Jordan Laser, Virginie Aris, Peng Lee, Khush Mittal, Patricia Soteropoulos, Jian-Jun Wei.   

Abstract

Human uterine leiomyomas (ULMs) are the most common neoplasms of women. Many genes are dysregulated in ULMs and some of this dysregulation may be due to abnormal expression of micro-RNAs (miRNAs). In this study, 55 ULMs and matched myometrium were collected from 41 patients for microarray-based global miRNA expression analysis. Of 206 miRNAs examined, 45 miRNAs were significantly up- or down-regulated in ULMs in comparison to the matched myometrium (P < 0.001). The top five dysregulated miRNAs in ULMs are the let-7 family, miR-21, miR-23b, miR-29b, and miR-197. Four polycistronic clusters of miRNAs were either up- or down-regulated, but not in a mixed pattern, indicative of coordinated regulation of these miRNAs. Significance analysis revealed that subsets of miRNAs were strongly associated with tumor sizes and race. By prediction analysis we identified some important tumorigenic genes previously identified in ULMs that may be targeted by the dysregulated miRNAs. HMGA2 was identified as one of target genes of the let-7 family of miRNAs and has been found to be suppressed by let-7 in vitro. This article contains Supplementary material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17243163     DOI: 10.1002/gcc.20415

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  102 in total

1.  Dicing up microRNA gene expression profiles in normal and neoplastic smooth muscle cells.

Authors:  Joseph M Miano
Journal:  Am J Pathol       Date:  2010-06-21       Impact factor: 4.307

2.  Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas.

Authors:  J Browning Fitzgerald; Vargheese Chennathukuzhi; Faezeh Koohestani; Romana A Nowak; Lane K Christenson
Journal:  Fertil Steril       Date:  2012-06-22       Impact factor: 7.329

Review 3.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

Review 4.  Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.

Authors:  George A Calin; Carlo M Croce
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 6.  The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma.

Authors:  Xiaoping Luo; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

7.  Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression.

Authors:  Mun Chun Chan; Aaron C Hilyard; Connie Wu; Brandi N Davis; Nicholas S Hill; Ashish Lal; Judy Lieberman; Giorgio Lagna; Akiko Hata
Journal:  EMBO J       Date:  2009-12-17       Impact factor: 11.598

8.  The let-7 microRNA interfaces extensively with the translation machinery to regulate cell differentiation.

Authors:  Xavier C Ding; Frank J Slack; Helge Grosshans
Journal:  Cell Cycle       Date:  2008-10-12       Impact factor: 4.534

Review 9.  MicroRNAs in cancer.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

10.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.